[HTML][HTML] Safety and immunogenicity of a 100 μg mRNA-1273 vaccine booster for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
S Chalkias, H Schwartz, B Nestorova, J Feng, Y Chang… - medRxiv, 2022 - ncbi.nlm.nih.gov
S Chalkias, H Schwartz, B Nestorova, J Feng, Y Chang, H Zhou, FJ Dutko, DK Edwards…
medRxiv, 2022•ncbi.nlm.nih.govObjectives: Evaluate safety and immunogenicity of 100-μg of mRNA-1273 booster dose in
adults. Design: Open-label, Phase 2/3 study. Setting: Multicenter study at 8 sites in the US
Participants: The mRNA-1273 100-μg booster was administered to adults who previously
received a two dose primary series of 100-μg mRNA-1273 in the phase 3 Coronavirus
Efficacy (COVE) trial, at least 6 months earlier. Intervention: Lipid nanoparticle containing
100-μg of mRNA encoding the spike glycoprotein of SARS-CoV-2 (Wuhan-HU-1). Main …
adults. Design: Open-label, Phase 2/3 study. Setting: Multicenter study at 8 sites in the US
Participants: The mRNA-1273 100-μg booster was administered to adults who previously
received a two dose primary series of 100-μg mRNA-1273 in the phase 3 Coronavirus
Efficacy (COVE) trial, at least 6 months earlier. Intervention: Lipid nanoparticle containing
100-μg of mRNA encoding the spike glycoprotein of SARS-CoV-2 (Wuhan-HU-1). Main …
Objectives:
Evaluate safety and immunogenicity of 100-μg of mRNA-1273 booster dose in adults.
Design:
Open-label, Phase 2/3 study.
Setting:
Multicenter study at 8 sites in the US
Participants:
The mRNA-1273 100-μg booster was administered to adults who previously received a two dose primary series of 100-μg mRNA-1273 in the phase 3 Coronavirus Efficacy (COVE) trial, at least 6 months earlier.
Intervention:
Lipid nanoparticle containing 100-μg of mRNA encoding the spike glycoprotein of SARS-CoV-2 (Wuhan-HU-1).
Main Outcomes and Measures:
Solicited local and systemic adverse reactions, and unsolicited adverse events were collected after vaccination. Primary immunogenicity objectives were to demonstrate non-inferiority of the neutralizing antibody (nAb) response against SARS-CoV-2 based on the geometric mean titer (GMTs) and the seroresponse rates (SRRs)(booster dose vs. primary series in a historical control group). nAbs against SARS-CoV-2 variants were also evaluated.
Results:
The 100-μg booster dose had a greater incidence of local and systemic adverse reactions compared to the second dose of mRNA-1273 as well as the 50-μg mRNA-1273 booster in separate studies. The geometric mean titers (GMTs; 95% CI) of SARS-CoV-2 nAbs against the ancestral SARS-CoV-2 at 28 days after the 100-μg booster dose were 4039.5 (3592.7, 4541.8) and 1132.0 (1046.7, 1224.2) at 28 days after the second dose in the historical control group [GMT ratio= 3.6 (3.1, 4.2)]. SRRs (95% CI) were 100%(98.6, 100) at 28 days after the booster and 98.1%(96.7, 99.1) 28 days after the second dose in the historical control group [percentage difference= 1.9%(0.4, 3.3)]. The GMT ratio (GMR) and SRR difference for the booster as compared to the primary series met the pre-specified non-inferiority criteria. Delta-specific nAbs also increased (GMT fold-rise= 233.3) after the 100-μg booster of mRNA-1273.
Conclusions and Relevance:
The 100-μg mRNA-1273 booster induced a robust neutralizing antibody response against SARS-CoV-2, and reactogenicity was higher with the 100-μg booster dose compared to the authorized booster dose level in adults (50-μg). mRNA-1273 100-μg booster dose can be considered when eliciting an antibody response might be challenging such as in moderately or severely immunocompromised hosts.
Trial Registration:
ncbi.nlm.nih.gov